SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 36674.
  • 2
    Alarcon-Segovia D, Delezé M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine (Baltimore) 1989; 68: 35365.
  • 3
    Cines DB, McRae KR. The antiphospholipid-protein syndrome. J Clin Immunol 1995; 15: 86100.
  • 4
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 41204.
  • 5
    Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41: 20514.
  • 6
    Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2-glycoprotein I. Arthritis Rheum 1998; 41: 21523.
  • 7
    Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1996; 93: 16249.
  • 8
    Asano T, Furie BC, Furie B. Platelet binding properties of monoclonal lupus autoantibodies produced by human hybridomas. Blood 1985; 73: 125460.
  • 9
    Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 132832.
  • 10
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti–β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40: 55161.
  • 11
    Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 22119.
  • 12
    Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 30114.
  • 13
    Rosen SD. Cell surface lectins in the immune system. Semin Immunol 1993; 5: 23747.
  • 14
    Kaplanski G, Farnarier C, Tissot O, Pierres A, Benoliel AM, Alessi MC, et al. Granulocyte-endothelium initial adhesion: analysis of transient binding events mediated by E-selectin in a laminar shear flow. Biophys J 1993; 64: 192233.
  • 15
    Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767804.
  • 16
    Kaplanski G, Fabrigoule M, Boulay V, Dinarello CA, Bongrand P, Kaplanski S, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-α-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158: 543541.
  • 17
    Gearing AJH, Hemingway I, Pigott R, Hugues J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci 1992; 667: 32431.
  • 18
    Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 50612.
  • 19
    Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993; 36: 51927.
  • 20
    Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098102.
  • 21
    Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of circulating form of vascular cell adhesion molecule-1: raised in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993; 92: 4128.
  • 22
    Harris EN, Baguley E, Asherson RA, Hugues GRV. Clinical and serological features of the anti-phospholipid syndrome (APS) [abstract]. Br J Rheumatol 1987; 26 Suppl 2: 19.
  • 23
    Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for the primary antiphospholipid syndrome. J Rheumatol 1993; 20: 18024.
  • 24
    Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195207.
  • 25
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 26
    Branch DW, Silver RM. Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Lupus 1996; 5: 40913.
  • 27
    Zörhens G, Ambrust T, Pirzer U, Meyer zum B üshenfelde KH, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis. Hepatology 1993; 18: 798802.
  • 28
    Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C: correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 227784.
  • 29
    Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CGM. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97: 43944.
  • 30
    Janssen BA, Luqmani RA, Gordon C, Hemingway IH, Bacon PA, Gearing AJH, et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33: 11126.
  • 31
    Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 83441.
  • 32
    Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995; 154: 476877.
  • 33
    Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1, CD54) and vascular cell adhesion molecule-1 (VCAM, CD106). Blood 1998; 92: 125967.
  • 34
    Bruijn JA, Dinklo NJCM. Distinct patterns of expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial-leukocyte adhesion molecule-1 in renal disease. Lab Invest 1993; 69: 32935.
  • 35
    Alpers CE, Hudkins KL, Davis CL, Marsh CL, Riches W, McCarty JM, et al. Expression of vascular cell adhesion molecule-1 in kidney allograft rejection. Kidney Int 1993; 44: 80516.